Please login to the form below
Evan Lippman joins Aileron Therapeutics
He has experience at EMD Serono, Pfizer and AstraZeneca
Aileron Therapeutics has added to its senior team with the appointment of Evan Lippman as its first chief financial and business officer.
The addition comes as the US biopharma prepares to advance its lead oncology candidate ALRN-6924 into clinical trials.
In Lippman Aileron gains the expertise of a man with great experience in life sciences. Most recently Lippman help a senior VP role at EMD Serono heading the strategy for its US neurology franchise.
Highlights of his career include a spell as executive director at AstraZeneca where he led on huge brands such as Crestor (rosuvastatin calcium) and Nexium (esomeprazole) and heading US business development at the same company.
Lippman's other big pahrma experience includes a period at Pfizer as executive director, worldwide business development and strategic planning.
Featured jobs
-
Associate Medical Director
-
Excellent PTO, bonus and 401k package
- CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...
-
EXCELLENT DAY RATES AVAILABLE
-
Senior Account Manager
-
Competitive Salary Offered
-
Account Manager / Account Director
-
Competative
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
Systematic Reviewer - Oxford
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Manager- Healthcare Advertising
-
Negotiable
-
Account Manager
-
Negotiable
- Manager - Immunology, Therapeutic Area Communications & Publ...
-
Competitive Salary Offered
-
Experienced Medical Writers
-
Competitive Salary and Benefits
- Account Executive/ Senior Account Executive
-
competitive Salary Offfered
Subscribe to our email news alerts
- Blue Latitude Health joins Fishawack Group of Companies
- Clark Health Communications to bring AI to the forefront with new deal
- Merck exec steps down, two takes his place
- NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done
- FDA takes aim at pharma’s biosimilar-delaying tactics
- Circassia seeks shift to AIM after failing LSE criteria
PMHub
Synergy Vision
Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...
Latest intelligence
- Report: Achieving launch excellence in the challenging healthcare markets of today
- Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
- What is blockchain and why should i care - Richard Springham
- Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
- NHS medicines optimisation milestone
- Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Quick links
Infographics
